September 8, 2011
William Irish, PhD will present at the Food and Drug Administration (FDA) as part of the public workshop on the Effects of Ischemia Reperfusion Injury (IRI) on Outcomes in Kidney Transplant, taking place September 8-9, 2011. Dr. Irish will present on the topic of Cold Machine Perfusion versus Static Cold Storage for Standard Criteria Donor, Extended Criteria Donor, and Donation after Cardiac Death Kidneys.
Dr. Irish, Vice President of Health Outcomes and Biostatistics at CTI Clinical Trial and Consulting Services (CTI), is an internationally recognized expert in the areas of study design and analysis. He has been a leading resource in transplantation for more than twenty years, beginning as a faculty member at the University of Pittsburgh and continuing throughout his career in various biotechnology and pharmaceutical areas.
According to the FDA’s website, “This public workshop is intended to obtain information from health care providers, academia, and industry on various aspects of the pathophysiology, clinical management, and outcomes following IRI. The meeting will include a discussion of animal models, devices, and clinical trial design. The input from this public workshop will help in developing topics for further discussion and may serve to inform recommendations on clinical trial design for products for the mitigation of IRI and/or for the prophylaxis and/or treatment of delayed graft function (DGF) and related conditions in kidney transplant recipients.”